Transbuccal delivery of 5-aza-2′-deoxycytidine: Effects of drug concentration, buffer solution, and bile salts on permeation

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  Mahalingam, Ravichandran ^a   Ravivarapu, Harish ^b   Redkar, Sanjeev ^b   Li, Xiaoling ^a   Jasti, Bhaskara R ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SuperGen Inc   (United States)

Author keywords

Bile salts; Buccal; Decitabine; Ionic strength; Transmucosal

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BILE SALT; BUFFER; GLYCOCHOLATE SODIUM; PHOSPHATE; TAUROCHOLIC ACID; AZACITIDINE; BILE ACID; DRUG DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIC STRENGTH; NONHUMAN; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STEADY STATE; ANIMAL; CHEEK; METABOLISM; MOUTH MUCOSA; OSMOLARITY; PERMEABILITY; SWINE;

ANIMALS; AZACITIDINE; BILE ACIDS AND SALTS; BUFFERS; CHEEK; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MOUTH MUCOSA; OSMOLAR CONCENTRATION; PERMEABILITY; SWINE;

EID: 34547126907     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0803051     Document Type: Article

References (34)

1. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85-93.
2. Bouchard J, Momparler RL. Incorporation of 5-aza-2′-deoxycytidine-5′-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol. 1983;24:109-114.
3. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984;64:922-929.
4. Rivard GE, Momparler RL, Demers J. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk. Res. 1981;5:453-462.
5. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30:277-286.
6. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer. 1991;64:144-148.
7. Kantarjian HM, O'Brien SM, Estey E, et al. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997;11: S35-S36.
8. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957-2964.
9. Zagonel V, Lo Re G, Marotta G, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993;7:30-35.
10. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96:2379-2384.
11. Cunha KS, Reguly ML, Graf U, de Andrade HH. Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster. Mutat Res. 2002;514:95-103.
12. Momparler LF. 5-Aza-2-deoxycytidine: an overview. In: Momparler RL, De Vos D, eds. Proceedings of the Workshop on 5-Aza-2-Deoxycytidine. New York, NY: PCH Publication; 1990:9-15.
13. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993;7:51-60.
14. Richel DL, Colly LP, Lurvink E, Willeraze R. Comparison of the antileukemic activity of 5-aza-2-deoxycytidine (5-aza-dC) and 1-d-arabinofuranosylcytosine in rats with araC resistant and sensitive myelocytic leukemia. In: Momparler RL, De Vos D, eds. Proceedings of the Workshop on 5-Aza-2-Deoxycytidine. New York, NY: PCH Publication; 1990:77-87.
15. Haas PS, Wijermans P, Verhoef G, Lubbert M. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Leuk Res. 2006;30:338-342.
16. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11:S19-S23.
17. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
18. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley J, Agbaria R. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol. 2005;70:121-133.
19. Zhao M, Rudek MA, He P, et al. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:81-88.
20. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pham Sci. 1992;81:1-10.
21. Wertz PW, Squier CA. Cellular and molecular basis of barrier function in oral epithelium. Crit Rev Ther Drug Carrier Syst. 1991;8:237-269.
22. Sugawara M, Kurosawa M, Sakai K, Kobayashi M, Iseki K, Miyazaki K. Ionic strength has a greater effect than does transmembrane electric potential difference on permeation of tryptamine and indoleacetic; acid across Caco-2 cells. Biochim Biophys Acta. 2002; 1564:149-155.
23. Hoogstraate AJ, Senel S, Cullander C, Verhoef J, Junginger HE, Bodde HE. Effects of bile salts on transport rates and routes of FTIC-labelled compounds across porcine buccal epithelium in vitro. J Control Release. 1996;40:211-221.
24. Gandhi R, Robinson JR. Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid. Int J Pharm. 1992;85:129-140.
25. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm. 2001;51:93-109.
26. Samrat M, Uday M. Chemistry and biology of bile acids. Curr Sci. 2004;87:1666-1683.
27. Nielsen HM, Rassing MR. TR146 cells grown on filters as a model of human buccal epithelium, III: permeability enhancement by different pH values, different osmolality values, and bile salts. Int J Pharm. 1999;185:215-225.
28. Xiang J, Fang X, Li X. Transbuccal delivery of 2′,3′-dideoxycytidine: in vitro permeation study and histological investigation. Int J Pharm. 2002;231:57-66.
29. Hoogstraate AJ, Coos Verhoef J, Pijpers A, et al. In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. Pharm Res. 1996;13: 1233-1237.
30. Hoogstraate AJ, Verhoef JC, Tuk B, et al. In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs. J Pharm Sci. 1996;85: 457-460.
31. Senel S, Capan Y, Sargon MF. Enhancement of transbuccal permeation of morphine sulfate by sodium glycodeoxycholate in vitro. J Control Release. 1997;45:153-162.
32. Senel S, Hoogstraate A, Spies F, Verhoef J, Bodde H. Enhancement of in vitro permeability of porcine buccal mucosa by bile salts: kinetic and histological studies. J Control Release. 1994;32: 45-56.
33. Deneer VH, Drese GB, Roemele PE, et al. Buccal transport of flecainide and sotalol: effect of a bile salt and ionization state. Int J Pharm. 2002;241:127-134.
34. Jasti BR, Zhou S, Mehta RC, Li X. Permeability of antisense oligonucleotide through porcine buccal mucosa. Int J Pharm. 2000;208:35-39.